why choose us

First received: May 01, 2023

Clinical Trial: Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Blastoid Variant Mantle Cell Lymphoma

Study Type: INTERVENTIONAL


Official Title: Phase 1/2 Study of the Combination of Glofitamab, Venetoclax and Lenalidomide in Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

Brief Summary: This phase I/II trial tests the safety and effectiveness of glofitamab (with obinutuzumab pretreatment), venetoclax, and lenalidomide in treating patients with newly diagnosed, high risk mantle cell lymphoma.Glofitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread.Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors.It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell…

Read more